Zai Lab (ZLAB) Remains a Buy Amid Strong Commercial and Pipeline Momentum
As of November 27, Zai Lab Limited (NASDAQ:ZLAB) is a consensus Buy with over 90% analysts covering it having a Buy, Strong Buy, or equivalent rating.
Zai Lab Ltd (ZLAB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 987,043 | $33,450,887 | +170% | 0.01% |
| 2. | ADAR1 Capital Management Daniel Schneeberger | 868,780 | $29,442,954 | +3% | 2.77% |
| 3. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 791,193 | $26,813,531 | -10% | 1.57% |
| 4. | BioImpact Capital Mpm Capital | 745,060 | $25,250,083 | 4.13% | |
| 5. | Superstring Capital Management Ting Guo | 200,628 | $6,799,283 | +49% | 6.7% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.91 | 10,000 | $289,100.00 | 86,604 | 2025-09-10 | Filing | |
| $21.40 | 3,000 | $64,200.00 | 31,684 | 2024-05-13 | Filing | |
| $20.83 | 3,000 | $62,490.00 | 23,527 | 2024-03-01 | Filing | |
| $29.90 | 4,000 | $119,600.00 | 20,527 | 2023-12-14 | Filing | |
| $26.93 | 5,000 | $134,650.00 | 16,527 | 2023-11-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.78 | 14,328 | $283,407.84 | 27,737 | 2025-11-21 | Filing | |
| $26.83 | 240 | $6,439.44 | 17,444 | 2025-11-03 | Filing | |
| $34.25 | 456 | $15,616.63 | 17,184 | 2025-10-02 | Filing | |
| $36.24 | 6,641 | $240,643.28 | 76,604 | 2025-08-18 | Filing | |
| $36.24 | 1,883 | $68,232.39 | 42,065 | 2025-08-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,077,666 | $205,972,101 | 0.03% | |
| 2. | 4,701,711 | $159,340,986 | 0.01% | |
| 3. | 3,519,337 | $119,270,346 | 0.09% | |
| 4. | 2,291,372 | $77,654,597 | 0.96% | |
| 5. | 2,049,537 | $69,486,679 | 0.03% |
News See All
12 Oversold Global Stocks to Invest In
Appearing in an interview with CNBC on November 21, 2025, David Katz of Matrix Asset Advisors called widespread weakness a potential entry point, saying that the current correction is “much closer to...
Zai Lab Limited (NASDAQ:ZLAB) Q3 2025 Earnings Call Transcript
Operator: Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's Third Quarter 2025 Financial Results Conference Call. [Operator Instructions].
Zai Lab Limited (ZLAB): A Bull Case Theory
We came across a bullish thesis on Zai Lab Limited on Value investing subreddit by mrmrmrj. In this article, we will summarize the bulls’ thesis on ZLAB.
Zai Lab Limited (NASDAQ:ZLAB) Q2 2025 Earnings Call Transcript
Operator: Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's Second Quarter 2025 Financial Results Conference Call.
Zai Lab Ltd (ZLAB) Delivers Positive Results for Potential Gastric Cancer Treatment
Zai Lab Ltd (NASDAQ:ZLAB) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On June 30, Leerink Partners raised its price target for the stock to $75 from $73.
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen
Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a worried man.
Zai Lab (ZLAB) Delivers Positive ZL-1503 Trial Results in Treatment of Atopic Dermatitis
Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 biotech stocks screaming a buy.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)'s TTFields Therapy Succeeds in Phase 3 Trial
Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed landmark results from the Phase 3 PANOVA-3 trial at the 2025 ASCO Annual Meeting, marking the first therapy to show statistically...